In Honor of Nobel Laureate Prof. M Stanley Whittingham
| ANTIOXIDANTS AS A POTENTIAL TREATMENT FOR ULCERATIVE COLITIS Yoshiaki Harakawa1; Fuhua Yang1; Toshikazu Yoshikawa2; Haruhiko Inufusa1; 1GIFU UNIVERSITY, Gifu, Japan; 2LOUIS PASTEUR MEDICAL RESEARCH CENTER, Kyoto, Japan; PAPER: 105/Oxidative/Regular (Oral) OL SCHEDULED: 17:50/Tue. 28 Nov. 2023/Dreams 1 ABSTRACT: Ulcerative colitis (UC) is defined as a diffuse, nonspecific inflammation of unknown origin that continuously damages the colonic mucosa from the rectal side, often leading to erosions and ulcers. It is associated with frequent abdominal pain and sometimes diarrhea with bloody stools. There are more than 160,000 cases of the disease in Japan, but no cure has yet been established. Although the exact cause of the disease has not yet been clarified, oxidative stress has long been implicated, as it has been observed that reactive oxygen species (ROS) increase in inflamed tissues. Reduction of ROS and improvement of oxidative stress may improve UC. Twendee X (TwX, Oxicut®︎) is an antioxidant supplement containing eight active ingredients consisting of vitamins and amino acids; Twendee Mtcontrol (TwM, Mtcontrol®︎) is a supplement with seven active ingredients added to TwX to increase its antioxidant capacity. The therapeutic effects of antioxidants were tested in a mouse model of UC with dextran sodium sulfate (DSS), a commonly used treatment in UC research. TwX and TwM were found to ameliorate the negative physical effects of UC in the DSS model. The results suggest that antioxidant treatment may be effective for UC. References: 1. Japan Intractable Diseases Information Center. 2023. https://www.nanbyou.or.jp/. Accessed 15 Jun 2023.<br />2. Lih-Brody L, Powell SR, Collier KP, Reddy GM, Cerchia R, Kahn E, Weissman GS, Katz S, Floyd RA, McKinley MJ, Fisher SE, Mullin GE. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci. 1996 Oct;41(10):2078-86.<br />3. Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021 Jun;56(6):489-526.<br />4. Kim JJ, Shajib MS, Manocha MM, Khan WI. Investigating intestinal inflammation in DSS-induced model of IBD. J Vis Exp. 2012 Feb 1;(60):3678. |
